Skip to main content

Table 2 Descriptive and comparative statistics of the different studied parameters in the different patient subgroups

From: Growth differentiation factor 15: an emerging diagnostic biomarker of liver fibrosis in chronic hepatitis C patients

Parameter Liver fibrosis patient group (n = 55) Kruskal-Wallis test
Subgroup І F0-F1 Subgroup II F2 Subgroup III F3–F4 H p value
n. Median Q1–Q3 n. Median Q1–Q3 n. Median Q1–Q3
Age (years) 16 32 28–47.25 12 37.5 32–47.5 22 52.5 43.75–57.5 12.522 0.002
Weight (kg) 18 73.5 68–78.25 13 75 67.5–86.5 24 70 66.5–84.5 0.273 0.873
AST (IU/L) 18 28 21–36.25 13 25 19–43 24 50.5 8.75–72.5 20.873 0
ALT (IU/L) 18 27 20.25–43.5 13 35 21.5–48 24 47 35.5–64.25 9.367 0.009
T. bilirubin (mg/dl) 18 0.65 0.475–0.8 13 0.6 0.35–0.8 24 1 0.8–1.75 16.122 0
D. bilirubin (mg/dl) 18 0.2 0.1–0.2 13 0.2 0.1–0.3 24 0.3 0.2–0.7 13.276 0.001
Albumin (g/L) 17 4.1 3.95–4.45 13 4.2 4–4.5 24 3.55 3.2–4.1 14.857 0.001
Platelets (10^3/ul) 18 232 188.25–256 13 256 219–295.5 24 135 91–223.75 15.835 0
INR 18 1 0.987–1.025 13 1 1–1.1 23 1.1 1–1.3 10.895 0.004
AFP (IU/ml) 9 2.5 1.2–5.45 11 2.9 1.9–4.5 23 9.2 2.9–13.6 9.89 0.007
GDF-15 (ng/L) 18 340 220–500 13 500 405–510 24 415 335–587.5 5.185 0.075
  1. Q1–Q3* = interquartile range (25th–75th percentiles); p value > 0.05 is non-significant; p value < 0.01 is highly significant